Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 7:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,153 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Stage IV Non-small Cell Lung Cancer (NSCLC) Clear all
Terminated Phase 1Phase 2 Interventional

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

NCT01455389
View directory record Official record
Conditions
Lung Cancer
Interventions
DOTAP:Chol-TUSC2, Erlotinib, Dexamethasone, Diphenhydramine
Drug
Lead sponsor
Genprex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 1 Interventional Results available

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

NCT03229278
View directory record Official record
Conditions
Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Bladder Carcinoma, Recurrent Classical Hodgkin Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Renal Cell Carcinoma, Stage III Bladder Cancer, Stage III Lymphoma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Renal Cell Cancer, Stage III Skin Melanoma, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Skin Melanoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Lymphoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Solid Neoplasm
Interventions
Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer

NCT02073968
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
Interventions
Carboplatin, Computed Tomography, Intensity-Modulated Radiation Therapy, Paclitaxel, Positron Emission Tomography, Proton Beam Radiation Therapy
Drug · Procedure · Radiation
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2024 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00326599
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, cediranib maleate, gemcitabine hydrochloride
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
154
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 95 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 7, 2026, 7:55 PM EDT
Terminated Phase 2 Interventional Results available

The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere) [SMART] Trial for Non-Small Cell Lung Cancer (NSCLC)

NCT00887315
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Docetaxel and cisplatin, Docetaxel and cisplatin Plus Hypofractionated Radiotherapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 6, 2013 · Synced Oct 7, 2026, 7:55 PM EDT
Recruiting No phase listed Observational

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

NCT03042221
View directory record Official record
Conditions
Non-Small Cell Carcinoma of Lung, TNM Stage 4, Non-Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROSE Cluster 1, BRAF V600E
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 2 Interventional

Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

NCT00097214
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Carboplatin, Cetuximab
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Bentonville, Arkansas • Tucker, Georgia • Evanston, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2010 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

NCT00874848
View directory record Official record
Conditions
NSCLC
Interventions
Imprime PGG Injection, Cetuximab, Paclitaxel, Carboplatin
Biological · Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
Augusta, Georgia • Terre Haute, Indiana • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 7, 2026, 7:55 PM EDT
Not listed Phase 2 Interventional

Combination Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00005825
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, mitomycin C, tretinoin, vinorelbine tartrate
Drug
Lead sponsor
Raghu Nandan, M.D., Inc
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 7, 2026, 7:55 PM EDT
Terminated Phase 2 Interventional Results available

Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC

NCT00519831
View directory record Official record
Conditions
Lung Cancer
Interventions
cetuximab, vinflunine
Biological · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Burlington, North Carolina • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 7, 2026, 7:55 PM EDT
Completed No phase listed Observational

Tumor Response to Pemetrexed Disodium in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Enrolled in Clinical Trial MCCRC-RC0524

NCT00898820
View directory record Official record
Conditions
Lung Cancer
Interventions
gene expression analysis, polymorphism analysis, protein expression analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer

NCT04120454
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Pembrolizumab, Ramucirumab
Biological
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 7, 2026, 7:55 PM EDT
Active, not recruiting Phase 1 Interventional

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

NCT05334329
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Antineoplastic Immune Cell, Atezolizumab, Biospecimen Collection, Cyclophosphamide, Fludarabine
Biological · Procedure · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT02444741
View directory record Official record
Conditions
Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Proton Beam Radiation Therapy, Radiation Therapy, Stereotactic Body Radiation Therapy
Radiation · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 7, 2026, 7:55 PM EDT
Terminated Phase 1 Interventional Results available

Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer

NCT02083679
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine, Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed, Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel, Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Oct 7, 2026, 7:55 PM EDT
Recruiting No phase listed Observational

Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects

NCT06221800
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Microbiome
Diagnostic Test
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 1 Interventional

Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer

NCT00014430
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, vinorelbine ditartrate
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 1 Interventional Results available

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT02588612
View directory record Official record
Conditions
Neoplasms
Interventions
letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Miami, Florida • Tampa, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 7, 2026, 7:55 PM EDT
Active, not recruiting Phase 3 Interventional

Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer

NCT05502237
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Zimberelimab, Domvanalimab, Pembrolizumab, Carboplatin, Cisplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
11
States / cities
Whittier, California • Washington D.C., District of Columbia • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00729612
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, protein expression analysis, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Greg Otterson
Other
Eligibility
18 Years to 120 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

NCT03409614
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
REGN2810, REGN2810/chemo/ipi, Chemotherapy, Placebo
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
789 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
9
States / cities
Rancho Mirage, California • Riverside, California • Whittier, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 7, 2026, 7:55 PM EDT
Recruiting Phase 3 Interventional

Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

NCT06096844
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Nab-paclitaxel, Paclitaxel, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Questionnaire Administration
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
70 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
326
States / cities
Fayetteville, Arkansas • Fort Smith, Arkansas • Rogers, Arkansas + 256 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Not applicable Interventional Results available

S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)

NCT02728596
View directory record Official record
Conditions
Febrile Neutropenia, Stage 0 Breast Cancer, Stage 0 Colorectal Cancer, Stage 0 Non-Small Cell Lung Cancer, Stage I Colorectal Cancer, Stage IA Breast Cancer, Stage IA Non-Small Cell Lung Carcinoma, Stage IB Breast Cancer, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Breast Cancer, Stage IIA Colorectal Cancer, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Breast Cancer, Stage IIB Colorectal Cancer, Stage IIB Non-Small Cell Lung Carcinoma, Stage IIC Colorectal Cancer, Stage IIIA Breast Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IIIC Colorectal Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
Interventions
Preventive Intervention, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
3,665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
159
States / cities
Jonesboro, Arkansas • Martinez, California • Augusta, Georgia + 134 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 7, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen

NCT02066636
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
127
States / cities
Mobile, Alabama • Goodyear, Arizona • Phoenix, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 7, 2026, 7:55 PM EDT